A new clinical trial to determine whether a third dose of vaccine will improve the immune response for people who have weakened immune systems is launching in the UK.
www.news-medical.net
...клиничка студија за трета доза завршува 2022 год,
The FDA authorized the use of an additional dose of the Pfizer-BioNTech or Moderna COVID-19 Vaccines in certain immunocompromised individuals.
www.fda.gov
After a thorough review of the available data, the FDA determined that this small, vulnerable group may benefit from a third dose of the Pfizer-BioNTech or Moderna Vaccines,”
...трета бустер доза само за одредена група на имунокомпромитивни особи, одобрена од ФДА,
,, FDA is especially cognizant that immunocompromised people are particularly at risk for severe disease. The FDA evaluated information on the use of a third dose of the Pfizer-BioNTech or Moderna Vaccines in these individuals and determined that the administration of third vaccine doses may increase protection in this population,,
,,Initial results are expected later this year to inform the UK's COVID-19 vaccine deployment in these specific at-risk groups. The trial will follow the patients to mid-2022 and offer more detailed information at that stage about the immune responses that develop in these groups...,,
COVID-19 vaccines protect against COVID-19. Get safety info and more.
www.cdc.gov
...за обична популација се уште нема препорака за трета бустер доза!
,,,Although CDC does
not recommend additional doses or booster shots for any other population at this time,,